NSABP B-31

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of the study are 1) to compare the cardiotoxicity of four cycles of AC followed by four cycles of Taxol, with that of the same chemotherapy regimen plus Herceptin, in patients with operable, histologically node-positive breast cancer which overexpresses the HER2 protein; and 2)to determine whether, in this patient population, four cycles of AC followed by four cycles of Taxol and weekly Herceptin for one year is more effective in prolonging survival than four cycles of AC followed by four cycles of Taxol